OpenAI 收购 AI 生物科技初创 Orchestra Bio，加码生命科学业务
OpenAI acquires startup Orchestra Bio to beef up its biotech business
- 1OpenAI 收购成立四年的 AI 生物科技软件初创 Orchestra Bio，交易金额未披露。
- 2Orchestra 的智能体帮生物科技公司管理药物研发运营琐事，如财务追踪和临床试验排期。
- 3OpenAI 称 Orchestra 团队与技术将并入生命科学模型 Rosalind，该产品已有 Moderna 等客户。
- 4据报道 Orchestra 截至 2025 年累计融资约 2000 万美元，投资方包括 Andreessen Horowitz。
OpenAI 借收购把产品线延伸进制药这类高价值垂直行业，大型实验室正从通用模型走向行业软件。
- 影响：制药和生物科技企业多了一个由 OpenAI 直接投入研发的行业方案，且已有大型药厂在用；产品与实验室路线图重叠的行业软件初创，被并购或被功能覆盖的风险都更现实。
- 参考：生物科技企业可比较 Rosalind Workbench 与现有实验管理和数据分析工具的成本及覆盖面；行业软件创业者值得盘点自家产品与 OpenAI、Anthropic 方向的重叠清单，把合作或出售提前纳入选项。
- 依据：交易条款未披露；融资约 2000 万美元为媒体报道口径，Rosalind 客户 Moderna、Novo Nordisk 为 OpenAI 自述，暂无独立验证。
In Brief
Posted:
1:35 PM PDT · October 20, 2026
OpenAI on Tuesday acquired a four-year-old AI biotech software startup called Orchestra Bio, the company announced via its website. Terms of the deal were not disclosed, but the startup had reportedly raised around $20 million as of 2025 from backers like Andreessen Horowitz, Atria, and 8VC.
Orchestra creates AI agents that help biotech companies manage the minutiae of drug discovery operations, from tracking finances to resolving scheduling issues with clinical trials.
OpenAI says it’s adding Orchestra’s team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results. OpenAI has already won some big names as customers for Rosalind, including, it says, Moderna and Novo Nordisk.
The acquisition is a classic example of how the biggest AI labs (namely OpenAI and Anthropic) are building ever more software for the biggest industries, like pharma. In the startup world, there is an ongoing fear that at any moment, the labs will launch new features and become competitors. In this case, Orchestra is getting absorbed, rather than stomped out.
来源：TechCrunch · AI · techcrunch.com